Clinical trials: asthma
Severe Asthma
PROPE Severe Asthma Study in Egypt
Asthma is a syndrome characterized by airway inflammation, reversible airway obstruction, and airway hyper-responsiveness. Patients present clinically with recurrent wheezing, shortness of breath, cough, and chest tightness.
- Trial name
- NCT06283290
- Where
- 4 sites in Egypt
- Volunteers
- 201 people
- Sponsor
- AstraZeneca
Asthma
No Resistance After Long Term Treatment SERETIDE
This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment…
- Trial name
- NCT00456313
- Testing
- FLIXOTIDE and SERETIDE
- Where
- 2 sites in Netherlands
- Sponsor
- GlaxoSmithKline
Severe Asthma
Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy
This is a multi-country, multicentre, observational cross-sectional one-visit study of patients suffering from severe asthma in primary and secondary care settings in Europe
- Trial name
- RECOGNISE (NCT03629782)
- Where
- 12 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 1,032 people
- Sponsor
- AstraZeneca
Asthma
A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma
The main objective of this study is to evaluate the safety and tolerability of multiple fixed doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).
- Trial name
- NCT00590720
- Testing
- MEDI528 50 mg
- Where
- 12 sites in United States, Canada
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Asthma
Study in Patients With Asthma
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.
- Trial name
- NCT00215397
- Testing
- Formoterol Fumarate
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dey
Allergy
Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Two-stage, prospective, observational, real-world study of HDM-SLIT-naïve children (aged 5-11) and adolescents (aged 12-17) consulting allergists or other specialist physicians in France for an HDM-induced allergy.
- Trial name
- PROTECT (NCT04004351)
- Volunteers
- 1,531 people
- Sponsor
- Stallergenes Greer
Asthma
A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
This study was intended to demonstrate that patients with standard and high immunoglobulin E (IgE) levels can be protected from allergen induced broncho-constriction by Xolair
- Trial name
- NCT00624832
- Testing
- Xolair
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis
Asthma
Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma
Primary purpose is to assess if IMA-638 is safe and improves asthma in subjects with persistent asthma.
- Trial name
- NCT00425061
- Testing
- IMA-638
- Where
- 82 sites in United States, Canada
- Volunteers
- 159 people
- Sponsor
- Pfizer
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block
The objective of this pivotal study is to evaluate the relative bioavailability of SYN010 HFA Inhaler and Symbicort 160/4.5μg in healthy volunteers with charcoal block.
- Trial name
- NCT02850484
- Testing
- Budesonide, Formoterol
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Intech Biopharm Ltd.
Asthma, Common Cold
Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)
This is a randomized, multi-center, double-blind, placebo-controlled study evaluating the efficacy of pleconaril nasal spray in preventing asthma exacerbation and common cold symptoms in asthmatic participants exposed to…
- Conditions
- Asthma, Common Cold, Picornavirus Infection, Rhinovirus
- Trial name
- NCT00394914
- Testing
- Pleconaril
- Volunteers
- 311 people
- Sponsor
- Merck Sharp & Dohme LLC
Bronchial Asthma
To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma
This is a randomized, assessor-blind, placebo controlled, multicenter, clinical endpoint bioequivalence study to compare the efficacy and safety of generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark…
- Trial name
- NCT05363202
- Testing
- Fluticasone propionate Inhalation Aerosol 44 mcg, FLOVENT HFA 44 mcg
- Where
- 11 sites in India
- Volunteers
- 790 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Asthma
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant.
- Trial name
- TRECONY (NCT07301736)
- Testing
- CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a, CHF718 pMDI with HFA-134a
- Where
- 167 sites in Argentina, Bosnia and Herzegovina and 12 more
- Volunteers
- 780 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects
The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is…
- Trial name
- NCT00517634
- Testing
- FP, SFC
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Asthma
Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers
The primary objective of this study is to evaluate the acceptance range with which two Symbicort Turbohaler batches could be declared bioequivalent in a bioequivalence setting.
- Trial name
- REFLI (NCT01668121)
- Testing
- Symbicort Turbohaler, Budesonide/formoterol Easyhaler
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.
- Trial name
- NCT02054130
- Testing
- MEDI9929 70 mg, MEDI9929 210 mg, MEDI9929 280 mg
- Where
- 107 sites in United States, Bulgaria and 10 more
- Volunteers
- 584 people
- Sponsor
- MedImmune LLC
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00776984
- Testing
- tiotropium 5mcg/day
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 453 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma
The primary objectives are to determine the effect of ONO-6950 200 mg QD versus placebo administered for 8 days on early asthmatic response (EAR) and late asthmatic response (LAR) induced by inhaled allergen to determine the…
- Trial name
- NCT01551147
- Testing
- ONO-6950, Montelukast
- Where
- 5 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Ono Pharma USA Inc
Pulmonary Disease, Chronic Obstructive, Asthma
Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients
The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone and Formoterol using a gamma-scintigraphic technique after inhalation of a single dose of 99mTc-radiolabelled…
- Trial name
- NCT01176747
- Testing
- BDP/formoterol NEXT DPI
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Respiratory Syncytial Virus (RSV)
A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786
This study investigates the safety, tolerability and pharmacokinetics of single and repeat doses of PC786.
- Trial name
- NCT03236233
- Testing
- PC786 - Single doses, PC786 - Repeat doses
- Where
- United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Pulmocide Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.